Stock Financial Ratios, Dividends, Split History

SEB / Seaboard Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)4,430.61
Enterprise Value ($M)4,867.61
Book Value ($M)3,418.00
Book Value / Share2,919.99
Price / Book1.30
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 1,170,550
Common Shares Outstanding 1,170,550
Common Stock Shares Outstanding 1,170,550
Scoring Models
Piotroski F-Score7.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.06
Return on Assets (ROA)0.05
Return on Equity (ROE)0.08
Balance Sheet (mrq) ($M)
Quick Ratio2.68
Current Ratio3.69
Income Statement (mra) ($M)
Sales Revenue Goods Net4,693,000,000.00
Sales Revenue Net5,809,000,000.00
Sales Revenue Services Net1,009,000,000.00
Other Sales Revenue Net107,000,000.00
Operating Income232.00
Net Income246.00
Earnings Per Share Basic211.01
Cash Flow Statement (mra) ($M)
Cash From Operations245.00
Cash from Investing-266.00
Cash from Financing-266.00
Identifiers and Descriptors
Central Index Key (CIK)88121

Split History

Stock splits are used by Seaboard Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

12h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

13h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Trade war puts the hoof into U.S. pig part exports to China

5h reuters
CHICAGO (Reuters) - Before the U.S.-China trade war, American pig processors exported nine out of every 10 pigs’ feet and heads they shipped overseas to China and Hong Kong - for prices higher than they would fetch anywhere else.

Seaboard Corp confident of sealing deal for Kenya's Unga

2018-06-11 reuters
NAIROBI (Reuters) - Seaboard Corporation (SEB.A) is confident of buying out three quarters of minority shareholders in Kenyan agro-processor Unga Group (UNGA.NR) to allow it to eventually take the company private, Seaboard said on Monday. (3-0)

Tracking Kahn Brothers Portfolio - Q1 2018 Update

2018-05-02 seekingalpha
The portfolio continues to be very concentrated with the top five positions accounting for ~44% of the 13F holdings. (442-5)

Seaboard: Will Pork Tariffs Affect It?

2018-04-05 seekingalpha
Pork giant Seaboard (NYSEMKT:SEB) is great company that flies under the radar. The company is one of the largest pork producers in the world and also owns part of Butterball. (49-0)

China Retaliates: ETFs & Stocks on Radar

2018-04-03 zacks
The re-emergence of trade war fears has sent tremors across the Wall Street. This is because China has targeted about $3 billion in American exports in retaliation against Donald Trump’s tariff on steel and aluminum import (read: Trump Tariffs Put These Sector ETFs & Stocks in Focus). The second-largest country has slapped a duty on 128 American food products effective Apr 2. Of these, 120 products, including dried fruits, sparkling wine and stainless steel pipes, saw a new tariff of 15% while eight commodities, including pork products and aluminum scrap, saw a 25% tax hike. (16-0)

CUSIP: 811543107